For decades, cancer vaccines were a promise that never quite arrived. That changed this week. On October 22, 2026, Moderna and Merck released detailed results from a landmark Phase 3 trial showing that their personalized mRNA cancer vaccine, combined with the immunotherapy drug Keytruda, cut the risk of melanoma recurrence or death by 42% in patients whose tumors had been surgically removed. The data, from 1,137 patients with high-risk melanoma, will be presented at the European Society for Medical Oncology (ESMO) Congress in Madrid and have been accepted for publication in the New England Journal of Medicine.
It is the first time a personalized mRNA vaccine has demonstrated this kind of benefit in a large, late-stage trial when added to established immunotherapy. The companies say they are preparing to file for US regulatory approval, with the therapy potentially launching in 2027. Here is what the data show, how the vaccine works, and what still has to happen before it can reach patients.
What the new Phase 3 data show
The trial, called INTerpath-001, enrolled 1,137 patients with completely resected stage IIB to IV melanoma — meaning their tumors had been surgically removed but their cancer was considered high-risk for returning. Patients were randomly assigned, two-to-one, to receive either the investigational vaccine (known as intismeran autogene, formerly V940 or mRNA-4157) plus Keytruda, or a placebo plus Keytruda.
Over roughly two years, patients who received the combination saw:
- A 42% lower relative risk of recurrence or death compared with Keytruda alone — the headline figure.
- A 38% lower risk of the cancer spreading to distant sites (distant metastasis) or dying.
Treatment lasted about a year: the vaccine was given at 1 mg every three weeks for up to nine doses, while Keytruda (pembrolizumab) was given at 400 mg every six weeks for up to nine cycles. The detailed findings will be presented in the Presidential Symposium at ESMO 2026.
Importantly, the benefit held up across additional analyses of the data, and while overall survival data are not yet mature, the companies reported a favorable survival trend in the combination group. No major new safety concerns emerged: treatment-related side effects occurred in 95.8% of patients on the combination versus 90.0% on Keytruda alone, with serious (grade 3–5) events roughly similar between the groups — 14.2% versus 13.4%. The most common side effects in the vaccine arm were fever (52.2%), injection-site pain (51.0%), and fatigue (38.5%).
Professor Georgina Long, the trial's principal investigator and medical director of Melanoma Institute Australia, said the results have "the potential to make a foundational shift in how we treat patients with earlier-stage melanoma in the adjuvant setting," adding that the findings "support a fundamentally new and individualized approach to treating resected melanoma."
Why the smaller earlier trial matters too
INTerpath-001 did not come out of nowhere. A smaller Phase 2b trial, KEYNOTE-942, tested the same combination in 157 patients with resected stage IIIB–IV melanoma — and its long-term follow-up is arguably even more striking.
At four years, 72.4% of patients on the combination were still free of recurrence, versus 49.1% on Keytruda alone. Distant metastasis-free survival was 83.9% versus 65.4%. With up to five years of follow-up, the combination had reduced the risk of recurrence or death by 49% and the risk of distant spread or death by 59%, results published in the Journal of Clinical Oncology and presented at the 2026 ASCO annual meeting in Chicago.
That durability is the part oncologists find most compelling. Melanoma is notorious for returning years after surgery, even when scans look clean. The adjuvant window — the period right after surgery, before the cancer has a chance to regroup — is the best chance to keep it away. Keytruda has been the standard therapy in this window, but it does not help everyone. The new data suggest that adding a vaccine tailored to each patient's own tumor mutations widens the circle of patients who stay cancer-free.
How a personalized mRNA cancer vaccine actually works
This is not a preventive vaccine like the shots for flu or COVID-19. It is a treatment vaccine, custom-built for each individual patient from the genetic fingerprint of their own tumor. The process works in four steps:
- Sequence the tumor. After surgery, doctors genetically sequence the patient's tumor tissue and compare it to healthy DNA to find mutations that exist only in the cancer cells.
- Pick the targets. Algorithms select up to 34 mutated protein fragments — called neoantigens — that the immune system should learn to recognize. (Neoantigens are mutated pieces of protein found on cancer cells but not on normal cells.)
- Build the mRNA instructions. Messenger RNA coding for those neoantigens is packaged into a lipid particle — the same delivery approach used in Moderna's COVID-19 vaccine. Once inside the patient's cells, the mRNA instructs them to produce copies of the tumor's mutated proteins.
- Train the immune system. The immune system treats these foreign proteins as intruders and builds a targeted T-cell response against them — new immune cells programmed to hunt down any remaining cancer cells carrying those exact mutations.
Keytruda, meanwhile, plays a supporting role: it removes a natural "brake" that cancer cells use to hide from immune attack, so the newly trained T cells can do their work. As one way to think about it, the vaccine provides the immune system with a wanted poster, and Keytruda takes the blinders off.
The personalization is what makes the approach powerful — and logistically demanding. Unlike a one-size-fits-all drug, each dose is a batch of one, built from scratch for a single patient's tumor. The same underlying idea, but built on different targets, could in theory be adapted to many cancers. It is the same genomic-medicine logic driving other frontiers of the field, including CRISPR approaches that target cancer gene fusions and other mutation-driven therapies, which we covered in our look at CRISPR breakthroughs targeting gene fusions.
Why melanoma is the proving ground
There are reasons this breakthrough arrived in melanoma first — and they are worth understanding, because they explain where mRNA cancer vaccines are likely to go next.
First, melanoma is one of the most mutated cancers. Ultraviolet radiation damages DNA across the skin, so by the time a melanoma becomes dangerous it carries an unusually large number of mutations. More mutations mean more neoantigens — more targets for a personalized vaccine to aim at.
Second, melanoma is already an immunotherapy-responsive cancer. Keytruda and similar drugs have transformed melanoma treatment over the past decade, proving that the immune system can control this particular disease when given the right help. The vaccine is building on a foundation that already works.
Third, the adjuvant setting matters. Treating patients whose visible tumor has been removed — when only microscopic disease may remain — gives the immune system its best possible odds. A smaller, hidden cancer is easier to overwhelm than a large established one.
And fourth, melanoma is a cancer people can catch early. A suspicious mole, a changing spot, a skin check — early detection is why dermatologists spend so much time with dermatoscopes. Surgery cures most early melanomas outright; it is the high-risk cases, the ones most likely to return, that the new therapy is designed for.
What stands between this trial and your doctor's office
A strong Phase 3 result is a milestone, not a finish line. Here is what must still happen:
Regulatory review. Moderna CEO Stephane Bancel said the companies are preparing to file for US approval and expect the vaccine to launch in 2027 — but regulators will scrutinize the full dataset, and approval is never guaranteed.
Overall survival. Recurrence-free and metastasis-free survival are meaningful endpoints — they measure whether the cancer stays away — but regulators and doctors ultimately want to see that patients live longer. Those data are not yet mature, only trending favorably.
Manufacturing at scale. Personalized therapy is hard to industrialize. Each dose requires sequencing a patient's tumor, selecting targets, and manufacturing a unique mRNA batch within a clinically useful window — reportedly a matter of weeks. Moderna says its process is purely enzymatic, requiring no cell cultures to be grown, which helps. But scaling from a trial of 1,137 patients to tens of thousands of real-world patients is a different engineering challenge.
Cost and access. Personalized medicines have historically been expensive and difficult to deliver as standard care. Whether health systems and insurers will cover a bespoke vaccine for every high-risk melanoma patient remains an open question — one that will shape how broadly the benefit is felt.
Beyond melanoma. The bigger question investors and scientists are already asking: how far does this extend? Merck and Moderna are testing the intismeran-Keytruda pairing in nine other studies, including trials in pancreatic and gastric cancer, three late-stage trials in non-small cell lung cancer, and an early lung cancer study using the vaccine alone. These are much harder targets than melanoma — cancers with fewer mutations and trickier immune environments. Cancer research is advancing on many fronts at once; for perspective on another fast-moving one, see our coverage of the recent glioblastoma drug breakthrough.
What this means for patients
Here is the part that matters most, stated plainly: this therapy is investigational and is not currently available outside of research settings. The 42% figure applies to the patients in this trial, not to melanoma patients in general.
If you or someone you love has melanoma, the actionable steps remain the ones that are already proven: regular skin checks, prompt attention to changing moles, and — after surgery for high-risk disease — a thorough conversation with your oncologist about adjuvant treatment options that are available today. Clinical trials may be an option for some patients; your doctor can help you understand eligibility.
This article is general information, not medical advice. Cancer treatment decisions are deeply personal and must be made with a qualified doctor who knows your case.
Still, the direction is unmistakable. An mRNA platform that was built for a pandemic is now showing it can be reprogrammed against the mutations of an individual's cancer — and keep that cancer from coming back. Genomic tools that read the fingerprint of a tumor, and even tools that read your DNA to reshape your health habits, are moving from the laboratory into medicine faster than most of us expected. For the first time, a personalized cancer vaccine has cleared the hardest bar in clinical research. That is a genuine breakthrough — and it may be the first of several.